Frequent epigenetic inactivation of p53 target genes in seminomatous and nonseminomatous germ cell tumors

被引:18
|
作者
Christoph, F. [1 ]
Kempkensteffen, C. [1 ]
Weikert, S. [1 ]
Krause, H. [1 ]
Schostak, M. [1 ]
Miller, K. [1 ]
Schrader, M. [1 ]
机构
[1] Univ Med Berlin, Charite, Dept Urol, D-12200 Berlin, Germany
关键词
seminoma; nonseminoma; promoter methylation; clinical stage; quantitative methylation specific polymerase chain reaction;
D O I
10.1016/j.canlet.2006.03.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hypermethylation of tumor-suppressor genes has been implicated in the pathogenesis of human cancers. This study was designed to examine the methylation profiles of a selected group of p53 target genes (APAF-I, CASP-8, DAPK-I, IGFBP-3) and to correlate the findings with the histopathological characterization of testicular germ cell tumors (TGCT). Promoter methylation status was analysed by highly sensitive real-time methylation-specific PCR in 46 primary TGCTs (26 seminomas and 20 nonseminomas) and 15 normal testicular tissue samples. APAF-1 methylation was detected in all of the seminomatous and nonseminomatous TGCTs as well as in 60% of normal testicular tissue. Methylation of DAPK-1 was frequent in seminomas (50%) and nonseminomas (20%), but not in normal testicular tissue (6%). The degree of DAPK-1 methylation correlated with the clinical stage of the disease (P=0.05) and was useful in differentiating seminomatous from nonseminomatous, and malignant from nonmalignant testicular tissue (P=0.04 and 0.02, respectively). The APAF-1 methylation index achieved a highly significant differentiation between seminomatous or nonseminomatous tissue and nonmalignant testicular tissue (P=0.0001). In testicular tumorigenesis, promoter methylation of specific p53 target genes occurs at early stage but to varying degrees. Methylation also occurs in normal testicular tissue, which is in contrast to findings in other urogenital malignancies. Further studies will be necessary to determine whether the methylation level may be used as marker for risk estimation, especially in clinical stage I disease. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:137 / 142
页数:6
相关论文
共 50 条
  • [21] Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function
    De Giorgi, Ugo
    Yuan, Juping
    Moroni, Mauro
    Veronese, Silvio
    Sartore-Bianchi, Andrea
    Broggini, Massimo
    Rosti, Giovanni
    Strebhardt, Klaus
    Ruffini, Pier Adelchi
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (03): : E275 - E281
  • [22] SUPPRESSOR GENES OF RB AND P53 TUMORS
    MAY, P
    BULLETIN DU CANCER, 1993, 80 (08) : 690 - 692
  • [23] Census and evaluation of p53 target genes
    Fischer, M.
    ONCOGENE, 2017, 36 (28) : 3943 - 3956
  • [24] Census and evaluation of p53 target genes
    M Fischer
    Oncogene, 2017, 36 : 3943 - 3956
  • [25] Preferential translation of p53 target genes
    Hisaoka, Miharu
    Schott, Johanna
    Bortecen, Toman
    Lindner, Doris
    Krijgsveld, Jeroen
    Stoecklin, Georg
    RNA BIOLOGY, 2022, 19 (01) : 437 - 452
  • [26] THE CORRELATION OF P53 PROTEIN EXPRESSION WITH PROLIFERATIVE ACTIVITY AND OCCULT METASTASES IN CLINICAL STAGE-I NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS
    ULBRIGHT, TM
    ORAZI, A
    DERIESE, W
    DERIESE, C
    MESSEMER, JE
    FOSTER, RS
    DONOHUE, JP
    EBLE, JN
    MODERN PATHOLOGY, 1994, 7 (01) : 64 - 68
  • [27] Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes
    Gomes, Nathan P.
    Espinosa, Joaquin M.
    CELL CYCLE, 2010, 9 (17) : 3428 - 3437
  • [28] Molecular analysis for p53 and mdm2 in intracranial germ cell tumors
    M. Iwato
    O. Tachibana
    Y. Tohma
    H. Nitta
    Y. Hayashi
    J. Yamashita
    Acta Neuropathologica, 2000, 99 : 21 - 25
  • [29] Molecular analysis for p53 and mdm2 in intracranial germ cell tumors
    Iwato, M
    Tachibana, O
    Tohma, Y
    Nitta, H
    Hayashi, Y
    Yamashita, J
    ACTA NEUROPATHOLOGICA, 2000, 99 (01) : 21 - 25
  • [30] EP300 as an epigenetic target in p53 wild-type tumors treated with cisplatin
    Robaszkiewicz, A.
    Gronkowska, K.
    ANNALS OF ONCOLOGY, 2022, 33 (08) : S1395 - S1395